Generic GPCR residue numbers - aligning topology maps while minding the gaps

Isberg, Vignir; de Graaf, Chris; Bortolato, Andrea; Cherezov, Vadim; Katritch, Vsevolod; Marshall, Fiona H; Mordalski, Stefan; Pin, Jean-Philippe; Stevens, Raymond C; Vriend, Gerrit; Gloriam, David E

Published in: Trends in Pharmacological Sciences

DOI: 10.1016/j.tips.2014.11.001

Publication date: 2015

Document version: Peer reviewed version

Document license: Unspecified

Generic GPCR residue numbers – aligning topology maps while minding the gaps

Vignir Isberg1, Chris de Graaf2, Andrea Bortolato3, Vadim Cherezov4, Vsevolod Katritch5, Fiona H. Marshall3, Stefan Mordalski6,7, Jean-Philippe Pin8,9, Raymond C. Stevens4,5, Gerrit Vriend10, and David E. Gloriam1

1 Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
2 Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands
3 Heptares Therapeutics Ltd, Welwyn Garden City, UK
4 The Bridge@USC, Department of Chemistry, University of Southern California, Los Angeles, CA 90089 USA
5 The Bridge@USC, Department of Biological Sciences, University of Southern California, Los Angeles, CA 90089 USA
6 Department of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
7 Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
8 Institute of Functional Genomics, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche 5203, Universités Montpellier, Montpellier, France
9 Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 661, Montpellier, France
10 Centre for Molecular and Biomolecular Informatics (CMBI), Radboudumc, Nijmegen, The Netherlands

Generic residue numbers facilitate comparisons of, for example, mutational effects, ligand interactions, and structural motifs. The numbering scheme by Ballesteros and Weinstein for residues within the class A GPCRs (G protein-coupled receptors) has more than 1100 citations, and the recent crystal structures for classes B, C, and F now call for a community consensus in residue numbering within and across these classes. Furthermore, the structural era has uncovered helix bulges and constrictions that offset the generic residue numbers. The use of generic residue numbers depends on convenient access by pharmacologists, chemists, and structural biologists. We review the generic residue numbering schemes for each GPCR class, as well as a complementary structure-based scheme, and provide illustrative examples and GPCR database (GPCRDB) web tools to number any receptor sequence or structure.

New era in GPCR research
G protein-coupled receptors (GPCRs) constitute the largest family of human cell surface receptors [1]. They respond endogenously to ions, neurotransmitters, lipids, carbohydrates, nucleotides, amino acids, peptides and proteins; and also sense light, pain, tastes, and odors [2]. Their abundance in human physiological systems, as well as their accessibility and druggability, have made them a major drug target family – ~30% of the marketed drugs act on GPCRs [3]. The GPCRs are typically classified into the classes A–F [4], or according to the alternative GRAFS (glutamate, rhodopsin, adhesion, frizzled/taste2, secretin) system for the human receptors [5] (Table 1). In recent years, the number of GPCR crystal structures has grown exponentially and are now available for all of the human classes (A–C, F), except the Taste type 2 receptors. These structures have revealed common conformational changes during receptor activation, allosteric modulation by ions, lipids, cholesterol, and water; as well as interactions with the G protein [6–8].

Generic residue numbers - maps to navigate GPCR topology
All GPCRs share a structural core of seven transmembrane (7TM) helices, making up the machinery for signal transduction across the cell membrane. The 7TM domain contains or is part of the binding site of class A and B1 receptor ligands, and serves as a site for allosteric modulation of class B2, C, and F GPCRs [9,10]. So far, 109 GPCRs have been drugged [11], the vast majority with ligands binding within the TM region [12]. The conserved 7TM scaffold allows for the alignment of sequences or structures to identify the corresponding residues, which are indexed with a generic residue number. Such generic residue numbers allow for comparison of, for example, mutant effects, ligand interactions, and structural features across receptor subtypes, species orthologs, or receptor subfamilies. For example, such residue numbers have been used to define the shared ligand-accessible residue positions within the TM bundle [13]. These conserved positions are common placeholders, while receptor sequences vary and so compose the unique mosaic responsible for ligand affinity and selectivity.
Table 1. Human GPCR classification and crystal structures

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>B</td>
<td>Secretin</td>
<td>Also referred to as B1</td>
<td>15</td>
<td>2013: Corticotropin-releasing factor receptor 1 [7] and Glucagon receptor [8]</td>
</tr>
<tr>
<td></td>
<td>Adhesion</td>
<td>Also referred to as B2</td>
<td>33</td>
<td>–</td>
</tr>
<tr>
<td>C</td>
<td>Glutamate</td>
<td>Includes Taste type 1 receptors</td>
<td>22</td>
<td>2014: Metabotropic glutamate receptor 1 [76] and 5 [77]</td>
</tr>
<tr>
<td>F</td>
<td>Frizzled</td>
<td></td>
<td>11</td>
<td>2013: Smoothened [78]</td>
</tr>
<tr>
<td>O (Other)</td>
<td>Taste2</td>
<td>Re-classified as own family [79], although originally grouped with Frizzled [2]</td>
<td>24</td>
<td>–</td>
</tr>
</tbody>
</table>

*Classes D and E do not exist in human, and are fungal mating pheromone receptors and cAMP receptors, respectively.

Class A GPCR residue numbering

The Ballesteros–Weinstein numbering scheme [14] is based on the presence of highly conserved residues in each of the seven transmembrane (TM) helices. It consists of two numbers where the first denotes the helix, 1–7, and the second the residue position relative to the most-conserved residue, defined as number 50. For example, 5.42 denotes a residue located in TM5, eight residues before the most-conserved residue, P5.50. The residue numbers can be counted directly within the receptor protein sequence (alignment); however, the reference residues are not conserved in all receptors and the numbering is therefore not always straightforward (class A conservation: N1.50: 98%, D2.50: 90%, R3.50: 95%, W4.50: 97%, P5.50: 78%, P6.50: 99%, P7.50: 88% [15]).

Alternative class A numbering schemes have been presented by Oliveira [16], Baldwin [17,18], and Schwartz [19,20]. They have a common basis in enumerating residue positions from the helix extracellular ends, aiming to assign residues located at the same depth in the membrane with the same names, for example 3.16 and 6.16 (this reverses the TM2, TM4, and TM6 sequences). However, none of the schemes, which use different starting points and numbers, succeeds because GPCR crystal structures have uncovered extensive variations in the length and inclination of TM helices. The alternative schemes differ in format: Oliveira numbers (the oldest numbering scheme) omit the dot separator to make the numbers computationally more accessible, and Baldwin and Schwartz helix numbers are denoted with roman numerals, I–VII.

Class B, C, and F GPCR residue numbering

Class B, C, and F schemes have been established using the same procedure as the class A Ballesteros-Weinstein system, but use unique reference positions (X.50) such that the residue numbers can be counted directly within the receptor protein sequence (alignment). The class B GPCR Wootten [21] scheme is based on the B1/secretin subclass, but the reference residues are the most conserved also for five of the B2/adhesion receptor helices and the remaining two, TM3–4, still display high conservation (E3.50 58% and W4.50 42%) [15]. This scheme was used in the publications of the crystal structures of both the glucagon receptor [22] and corticotropin-releasing factor receptor 1 (CRF1) [23]. The class C GPCR Pin [24] numbering was used in the publication of the metabotropic glutamate receptor 5 (mGlu5) crystal structure [25]. The class F GPCR Wang scheme was introduced in the recent publication of Smoothened (SMO) crystal structures [26]. In humans, this is a small class with only 11 members, and in cases where a helix has more than one fully conserved position, the one structurally closest to the class A Ballesteros-Weinstein was used as the reference position. Because all schemes use identical formatting, it has been suggested to append the class name (A–F) where clarification is needed, for example, 3.50b for class B Wootten numbers [27].

Cross-class GPCR residue numbering

The low sequence conservation between the GPCR classes has hitherto hindered (correct) sequence alignments, although some inter-class receptor modeling studies correctly aligned the majority of the seven helices (e.g., [28–30]). The structural conservation is higher and the recent crystallographic data have opened up for structure-based sequence alignments from class A to B [22,23,27], C [25,31], and F [32,33]. Some helices display large inter-class lateral deviations or different bending but, because adjacent helices are often translated in the same direction, structural multi-residue motifs with a shared functional mechanism are often conserved across the classes. The published cross-class residue comparisons have utilized the Ballesteros-Weinstein numbers, and where necessary included a class-specific number, for example Y7.53a.57b. Furthermore, reference cross-class alignments, based on the available crystal structures, are available in GPCRDB (http://www.gpcrdb.org; see below). Table 2 shows the alignment of the class specific Ballesteros-Weinstein numbers based on structural alignment of crystal structures of representative receptors from class A (bRho), B (Glucagon receptor), C (mGlu1), and F (SMO).

Example 1: class A/B common receptor activation motif in TM7

A Tyr residue Y7.53a.57b, conserved in both class A (Y7.53) and class B (Y7.57) GPCRs, has been proposed to play an important role in the activation of both receptor families (Figure 1) [34]. In the Glucagon receptor (class B GPCR) crystal structure [22] Y400.7.57b forms hydrogen bonds with
Table 2. Alignment of the class-specific generic residue numbers based on structural alignment of crystal structures of representative receptors from class A (bovine rhodopsin, bRho), B (glucagon receptor), C (metabotropic glutamate receptor 1, mGlu1), and F (Smoothen, SM0). Class-specific reference residue positions (X.50) for each of the seven TM helices are given in bold font.

<table>
<thead>
<tr>
<th>Helix</th>
<th>Class A (bRho)</th>
<th>Class B (GLPR)</th>
<th>Class C (mGluRI)</th>
<th>Class F (SM0)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TM1</td>
<td>G51(4,44a)</td>
<td>S152(3,50a)</td>
<td>G603(5,54b)</td>
<td>T241(1,43f)</td>
</tr>
<tr>
<td></td>
<td>N55(3,50a)</td>
<td>L161(5,54b)</td>
<td>T607(5,54b)</td>
<td>T245(1,43f)</td>
</tr>
<tr>
<td></td>
<td>T58(1,53a)</td>
<td>A159(1,57b)</td>
<td>V610(1,57b)</td>
<td>T248(1,50f)</td>
</tr>
<tr>
<td>TM2</td>
<td>L70(2,43b)</td>
<td>H177(2,50b)</td>
<td>C631(2,30b)</td>
<td>L267(2,43f)</td>
</tr>
<tr>
<td></td>
<td>D83(2,50a)</td>
<td>F184(2,57b)</td>
<td>I638(2,46f)</td>
<td>L274(2,41f)</td>
</tr>
<tr>
<td></td>
<td>L84(2,54a)</td>
<td>V185(2,56b)</td>
<td>F639(2,47c)</td>
<td>F275(2,50f)</td>
</tr>
<tr>
<td></td>
<td>F88(2,55a)</td>
<td>S189(2,62b)</td>
<td>Y642(2,50c)</td>
<td>S278(2,53f)</td>
</tr>
<tr>
<td>TM3</td>
<td>L131(3,44a)</td>
<td>E245(3,50b)</td>
<td>K678(3,50b)</td>
<td>A327(3,46f)</td>
</tr>
<tr>
<td></td>
<td>R135(3,50a)</td>
<td>L249(3,54b)</td>
<td>I394(3,54c)</td>
<td>W331(3,50h)</td>
</tr>
<tr>
<td>TM4</td>
<td>W161(4,50a)</td>
<td>W272(4,50b)</td>
<td>I714(4,40c)</td>
<td>W369(4,50h)</td>
</tr>
<tr>
<td></td>
<td>P171(4,54a)</td>
<td>P282(4,60b)</td>
<td>L724(4,50c)</td>
<td>I375(4,60f)</td>
</tr>
<tr>
<td>TM5</td>
<td>V211(4,50a)</td>
<td>P310(4,42c)</td>
<td>Y759(4,40c)</td>
<td>P407(4,50f)</td>
</tr>
<tr>
<td></td>
<td>P215(4,50a)</td>
<td>A314(4,50b)</td>
<td>Y763(4,50c)</td>
<td>V411(4,54f)</td>
</tr>
<tr>
<td></td>
<td>I219(5,44a)</td>
<td>N318(5,50b)</td>
<td>C767(5,54c)</td>
<td>G415(5,50f)</td>
</tr>
<tr>
<td>TM6</td>
<td>L262(5,44a)</td>
<td>G359(5,50b)</td>
<td>C759(5,47c)</td>
<td>L464(5,46f)</td>
</tr>
<tr>
<td></td>
<td>W265(5,48a)</td>
<td>E362(5,53b)</td>
<td>W798(5,50c)</td>
<td>F467(5,47f)</td>
</tr>
<tr>
<td></td>
<td>P267(5,53a)</td>
<td>V364(5,55b)</td>
<td>A800(5,52c)</td>
<td>C469(5,49f)</td>
</tr>
<tr>
<td></td>
<td>Y268(6,51a)</td>
<td>F365(6,54b)</td>
<td>F801(6,50c)</td>
<td>H470(6,50f)</td>
</tr>
<tr>
<td>TM7</td>
<td>A299(7,46a)</td>
<td>G393(7,50b)</td>
<td>V823(7,40c)</td>
<td>F526(7,46f)</td>
</tr>
<tr>
<td></td>
<td>P303(7,56a)</td>
<td>A397(7,54a)</td>
<td>L827(7,44c)</td>
<td>I530(7,50f)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P833(7,50c)</td>
<td>V327(7,56f)</td>
<td>V592(7,56f)</td>
</tr>
</tbody>
</table>

Example 2: class A/C unique features of conserved residues in TM6 involved in ligand binding and receptor activation

In both classes A and C, TM6 contains a highly conserved tryptophan at position 6.48a.50c. This residue occupies an equivalent position in both classes, but in the structures of the metabotropic glutamate receptors mGlu1 [31] and mGlu5 [25] TM6 has moved laterally away from TM7 compared to class A. In contrast with class A, this movement allows W6.50c to create a hydrogen bond to the backbone carbonyl of 5.44c, bridging TM6 to TM5. Despite this conformational difference, the aromatic residues W6.48a.50c and F6.41a.52c play a role in the ligand binding in both classes (allosteric ligands for class C), as shown in the class A [6,8] and C [25,31] crystal structures (Figure 2). Their role in ligand binding and potentially in receptor activation is supported by mutation studies for several class A amineergic [36,37], chemokine [38], adenosine [39], and lipid [40] receptors, as well as class C receptors mGlu1 [41], mGlu5 [42,43], and CASR (calcium-sensing receptor) [44,45].

Example 3: class A/B/C/F common hydrophobic core

In the helical bundle, TM3 represents a structural and functional hub [6] being centrally placed with contacts to all other helices except TM1. TM3 plays a central role in activation [6], which involves the upward movement of TM3 along its axis and a rotation of TM6 [7]. Comparisons of inactive and activated class A receptor structures have led to the proposal of a hydrophobic mechanism hindering activation that consists of the rearrangement of a core of highly conserved hydrophobic residues in 3.43a together with V/I/L6.40a, V/I/L6.41a, and F6.44a [7]. This core is well conserved in all human GPCRs: all classes A, B, C, and

---

Figure 1. Class A/B common receptor-activation motif in transmembrane (TM) helix TM7. Intracellular view of structural superposition of corticotropin-releasing factor receptor 1 (CRF1, magenta, PDB: 4KSY), the glucagon receptor (cyan, PDB: 4LRH), and the β2-adrenoceptor (yellow, PDB: 3SN6). The conserved Tyr residue Y3635.75A and in CRF1, the thermostabilizing mutation Y3635.75A are shown in stick representation. In the glucagon receptor the polar interactions of Y4005.75c with T3516.42b and E2455.50b residues are represented as broken lines.

Figure 2. Class A/C unique features of conserved residues in TM6 involved in ligand binding and receptor activation. Side view of rhodopsin (purple, PDB: 2X72) and the metabotropic glutamate receptor mGlu1 (green, PDB: 4OR2). 11-cis-retinal and FITM are shown in line representation. L2.43c and the aromatic residues W6.48a.50c and Y6.41a.52c are shown in stick representation. In mGlu5, the polar interaction between W6.50c and T5.44c is represented as a broken line. Abbreviation: FITM, 4-fluoro-N-[4-(6-isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl)-N-methylbenzamide.
F have a highly conserved hydrophobic residue in position 3.43a.47b.47c.47f (mainly L, M, L, and W; respectively) that forms contacts with at least two hydrophobic residues in the equivalent TM6 positions 6.40a.45b.42c.39f, 6.41a.46b.43c.40f, and 6.44a.49b.46c.43f (recently described in Bortolato et al.) [15,33]. Furthermore, in all classes except C the other side of TM3 has hydrophobic contact with a highly conserved W4.50abf (same index in all classes) on TM4 [15,33].

**Extracellular loop 2 residue numbering**

Sequence analysis shows that there is a large diversity in the lengths and compositions of the N- and C-termini as well as in the extracellular and intracellular loops connecting the TM helices of GPCRs [46]. Nevertheless, for the extracellular loop 2 (EL2) a similar residue-numbering scheme has been applied [41,47] in which EL2 residues are labeled 45.X, indicating the location between TM4 and TM5 (“45”) [47]. The reference position (X.50) is a conserved cysteine forming a disulfide bridge with a TM3 residue C3.25a.29b.29c.25f, which is fully (100%) conserved in the classes B, C, and F, and 88% conserved in class A [15,47]. The second extracellular loops of many GPCRs have approximately the same number of residues upstream and downstream of C45.50 [47]. However, the loop regions of GPCRs are structurally less conserved than the TM helices [6], and EL2 is no exception. Thus, in comparisons across receptor subfamilies the structural conservation is limited to the backbone of 45.50–45.52. This short stretch is still of high importance because the 45.52 sidechain is often directed into the 7TM binding pocket [47]. Longer loop modeling has to be reserved to receptors where there is a template with the same length in TM4–C45.50 and C45.50–TM5, respectively, and guided by experimental restraints. Moreover, although recent GPCR Dock challenges show that although the positions of specific EL2 residues close to C45.50 can be correctly predicted, computational modeling of complete EL2 structures is still highly challenging [48–50].

**Mind the gap – introducing a novel complementary crystal structure-based GPCR residue numbering**

Class A GPCRs have long been known to contain helix kinks in TM5–7 that are induced by highly conserved proline residues, which are unable to form backbone hydrogen bonds [51]. Upon receptor activation, they act as hinges that allow the helices to tilt inwards to tighten the ligand cavity and outwards to widen the G protein-binding pocket [7]. This does not affect the generic residue numbers because the best corresponding alignment of residues is obtained knowing that receptor structures are dynamic and the same helix in two receptors can in most cases tilt to adopt a similar position. Consequently, the GPCR 7TM was assumed to be uniformly shaped, leading to the long-standing principle to never insert gaps within sequence alignments of the TM helices.

As we entered the structural era, we discovered that the GPCR 7TM frequently contains distortions of another type: bulges and constrictions that are local to one helix turn, but offset the generic numbers of all following residues in the helix. This is because there is one additional residue in a bulged (α-helical), and one absent residue in a constricted (β-helical) helical turn, respectively. This causes a single unmatched position, in other words a gap in structure and sequence compared to the corresponding undistorted helix. To date, more than 110 crystal structures of 27 unique GPCRs, have uncovered nine bulges (Figures 3A–I) and six constrictions (Figures 3J–O) in TM1, TM2, TM4, TM5, TM6, and TM7 [52]. These range all classes A, B, C and F; and two constrictions are shared by two classes (Figures 3N–O). Some helical distortions affect only a specific receptor subtype (Figure 3J), whereas others are shared by the majority (Figures 3E, H, and O) or all (Figures 3I and O) members of a GPCR class. Of note, the highly conserved proline residues P6.50x50 and P7.50x50 are associated with kinks in all available class A GPCR structures, but entail only few (12%, Figure 3F) or no observed bulges, respectively, in other words, they lack the backbone hydrogen bond but have no amino acid insertion.

GPCRDB has implemented a complementary structure-based scheme that corrects for bulges and constrictions. The scheme is based on pairwise superposition of inactive receptor structures using the ‘WHAT IF’ program [53]. Each helix is analyzed separately, and a bulge or constriction is defined by comparison to an undistorted reference. The single bulge residue that protrudes the furthest (Figures 3A–I) is assigned the same number as the preceding residue following by a 1, for example, a bulge after residue 46 is given the number 461. The position lacking in a constriction (Figures 3J–O) is simply skipped in the residue numbering. Uncertain cases are put on a ‘waiting’ list of potential bulges/constrictions that require additional crystallographic evidence. GPCRDB numbers are assigned to all distortions, even those that seem to be shared by all members of a GPCR class. This is for two reasons. First, it allows cross-class structure/sequence alignments, and second, it future-proofs the residue numbers by avoiding updates should another class-member with an undistorted helix be crystallized.

To distinguish the GPCRDB scheme, it uses a unique separator x (e.g., 5x46) to denote that it is based on experimental structures, which are predominantly X-ray structures although NMR structures are also taken into account when available. For clarity, it is recommended to use the combination of the sequence- and structure-based numbers, for example 2.58x57, unless the comparison only includes crystallized receptors.

**Example 4: TM2 bulge affects chemokine and opioid receptor binding site residues**

Although most GPCR crystal structures contain an alpha bulge in TM2 [52] at position 2.55x551, chemokine receptors and opioid receptors contain a ST\[2.56\]XP\[2.58\] sequence motif that stabilizes a different helical conformation. Site-directed mutagenesis data probing the TM2–TM3 interface [54] and receptor–ligand interactions in chemokine receptors [38,55] were used to successfully predict the TM2 conformation of CXCR4 (chemokine (C–X–C motif) receptor 4) and interactions between W94\[2.60\] and D9\[2.63\] and
Figure 3. Bulges and constrictions in GPCR class A, B, C and F crystal structures. Bulged (A–I) and constricted (J–O) helical turns have one additional and lacking residue position, respectively, when superposed to an undistorted helix reference. The structural and sequence alignments of equivalent residues therefor contain a gap, which offsets all following generic residue numbers (gray). The GPCRDDB generic residue numbers (black) are structure-based and account for bulges and constrictions by numbering an extra residue as the preceding followed by a 1, for example 1.40x411, and by skipping a lacking position. To facilitate cross-class comparisons, their alignments have been assigned GPCRDB numbers for all classes. The percentages to the lower right of the structures represent the conservation/frequency of the bulge or constricted position. (Figure legend continued on the bottom of the next page.)
the co-crystallized 1T1t ligand prior to the CXCR4–1T1t crystal structure [56] in the GPCR Dock 2010 challenge [49,57] (Figure 4A). CXCR4 models based on an ungapped sequence alignment between CXCR4 and the crystal structure templates available at the time of this GPCR modeling competition (rhodopsin, adrenoceptors β1 and β2, and the adenosine receptor A2A R) incorrectly oriented W942.60 and D972.63 towards the membrane layer instead of towards the ligand-binding site [49,57]. Residues at positions 2.60 and 2.63 interact with co-crystallized ligands in CCR5 (chemokine C–C motif receptor) (W2.60, Y2.63), the κ receptor (kappa 1 opioid receptor) (Q1152.60, V1182.63) [58], and NOP receptor (opiate receptor like-1 receptor) (Q1072.60, D1102.63) [59] crystal structures. Moreover, mutagenesis studies indicate that 2.63 (K108 and N129, respectively) plays a role in the ligand selectivity of δ and μ opioid receptors [55,60]. These residues structurally align with residues L1012.64x63 and H932.64x63 in adrenoceptors β1 (Figure 4B) and β2, respectively, two examples of GPCRs that contain a bulge in TM2. L1012.64x63 interacts with carmesterol, dobutamine, and carvedilol (Figure 4B) in β2-adrenoceptor crystal structures[61,62], while BI-167107 interacts with H932.64x63, and FAUC50 covalently binds the H932.64x63 Cysteine mutant in β2-adrenoceptor crystal structures [35,63].

**Example 5: TM4 constriction affects the alignment of aminergic receptor binding site residues**

The TM4 of the aminergic histamine H1 receptor crystal structure [64] is constricted, directing W1584.55x57 (an important residue for H1R ligand binding based on mutation studies [65]) towards the aromatic ligand-binding pocket (Figure 4C). The aminergic muscarinic acetylcholine M2 and M3 receptor crystal structures [66,67] are not constricted in TM4, and the structurally equivalent position of the conserved tryptophan is 4.57. This again lines the ligand-binding site and makes hydrophobic/atomic contacts with the co-crystallized ligand, in accordance with mutation studies of W4004.57 in M2 [68] (Figure 4D). Furthermore, combined mutagenesis and protein-ligand modeling studies to explain ligand selectivity for histamine H3 and H4 receptors [69] and H2R species variants [70] indicate that the residues at position 4.57 (V1674.57 in H3R and N1474.57 in H2R) are directed towards the ligand-binding pocket. This suggests that the TM4 of H2R and H4R are undistorted, making the constriction unique for the H1R subtype.
Numbering made easy – residue-numbering web tools at GPCRDB

GPCRDB has been a major community resource for more than 20 years [15,71–73]. It contains reference data including the largest available collection of receptor mutants, crystal structures, 3D structure models in the inactive and active states, and sequence alignments for all species in UniProt. Recently, GPCRDB was equipped with a new suite of interactive web browser tools and diagrams; these include phylogenetic trees, sequence motif search (e.g., for a binding site), and receptor sequence plots (snake and helix box plots). Notably, for all of the above, correct alignment of residues in sequence and/or structure is crucial.

For pharmacologists, chemists, structural biologists, and others to use generic residue numbers, a more convenient way is needed than the manual generation of sequence alignments and assignment of residue numbers. Consequently, GPCRDB provides reference alignments and a series of residue-numbering tools. The sequence alignments are based on the available crystal structures and are gapped to account for bulges and constrictions (Figure 5A). GPCRDB supports alignments of all classes displaying both the sequence-based Ballesteros-Weinstein (A), Wootten (B), Pin (C), and Wang (F) numbering, as well as structure-based GPCRDB residue numbers. The alignments are followed by a consensus sequence and statistics on residue/property conservation, and can be downloaded for further analysis. A predefined set in the receptor selection allows alignment or lookup (below) of only the crystallized receptors.

Look-up tables show side-by-side listing of receptor-specific and generic residue numbers (Figure 5B). The tables can list multiple receptors, such as subtypes or species orthologs, to facilitate the inference of, for example, mutagenesis data or ligand interactions observed in crystal structure complexes. GPCR structures can be browsed or uploaded in Protein Data Bank (PDB) format to assign up to two generic numbering schemes to the TM residues (Figure 5C). The numbers are stored in the PDB file by replacing the B-factor of the C-alpha and carbonyl carbons and scripts are presented for visualization using PyMOL, Maestro, or MOE (Molecular Operating Environment). Finally, to allow compatibility and reinterpretation of published literature, the Utopia PDF reader [74] can be downloaded to annotate receptor residues with information from GPCRDB. A guide to generic GPCR residue numbering is presented in Box 1.

Potential exceptions and future directions

The sequence- and structure-based numbering systems share some limitations. Generic residues can only be assigned to receptor regions with a conserved structural fold, in other words the 7TM domain, whereas the termini and loops can only be compared, in the best case, within receptor subfamilies. Both systems also depend on sequence homology to produce sequence alignments, although this dependency decreases for the GPCRDB
analyzing as new crystal structure templates become available. In fact, there are seven alignments – one for each helix. Most receptors and helices have a sufficiently high overall sequence similarity, and the bulk of the others can be anchored on highly conserved residue positions (e.g., the X.50 references). The few remaining are mostly orphan receptors with atypical sequences [75].

Upcoming crystal structures are expected to reveal additional offsets of the sequence-based numbering, while improving the structure-based system. The flip-side of the coin is that this requires the GPCRDB numbers to be updated for the given subset of receptors and offset residue positions. The GPCRDB numbering scheme has been designed so that the numbers are adjusted only when a newly determined GPCR structure reveals a new bulge or constriction that has not been predicted by homology. It should be pointed out that all abundant offsets, affecting many receptors, have most likely already been covered. Firstly, all bulges (Figure 3A–I) have a proline residue 3–5 positions downstream, and in the largest class (A) there are no more highly conserved proline residues in the 7TM that allow additional frequent bulges. Secondly, most other bulges and constrictions have so far only been observed in a single crystal structure and have a low expected frequency, indicating that future adjustments will be limited to small receptor subfamilies or a subset of their members. Consequently, determination of structures covering novel receptor families will be the most valuable.

Conformational plasticity and flexibility are intrinsic features of individual receptors that have to be accounted for in any analysis and generalization of structural information for GPCRs. So far, generic structure-based numbering has shown good tolerance to conformational changes in 7TM region. Thus, our analysis shows that the bulges and constrictions do not change between multiple crystal structures of the same GPCR, when available, even though these structures were determined using different complexes, resolutions, stabilization constructs, or crystal packing forms. Even when relatively large conformational changes between different activation states are considered, the corresponding helical distortions do not involve formation of a full bulge/constriction. This does not preclude a possibility of such changes being found in some of the newly solved GPCR structures in the future – in this case careful analysis should be applied to understand the mechanism and exclude potential artifacts.

Concluding remarks

The first crystal structures of the class B, C, and F GPCRs have opened up the field for receptor function studies and drug design. In addition, cross-class sequence alignments can now be constructed, enabling us to uncover the common cogs and cranks within the 7TM machinery. We have described the schemes for generic numbering of such residue hotspots for chemical structure-activity relationships, pharmacological effects of receptor mutants, and structural mechanisms. Furthermore, the multiplicity of structures has uncovered helix bulges and constrictions, making it clear that the correct mapping of equivalent residues requires the mapping of sequence alignments based on crystallographic evidence. Herein, GPCRDB presents such reference structure-based alignments and residue numbers. It is recommended that a combination of sequence-based and structure-based GPCRDB numbers is used, for example 2.58x57, unless the comparison only includes crystallized receptors.

Acceptance by the GPCR community will initially be determined by simplicity – in other words counting numbers within the specific sequence (alignment) as compared to looking it up in the GPCRDB alignments or tables. In the longer term, it is more crucial how many offsets accumulate in the sequence-based numbering and how many can be accepted while still preserving the utility of the system such that the same number actually refers to the equivalent residues across different GPCRs. The GPCRDB numbering system has been fully endorsed by the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR). NC-IUPHAR, together with its database GuideToPharmacology [76], will be working closely with GPCRDB to encourage acceptance of this system by the wider GPCR community.

Acknowledgments

The Lundbeck Foundation provided financial support to V.I. and D.E.G., who was also funded by the Carlsberg Foundation. V.C., V.K., and R.C.S are supported by NIH grants U54 GM094618 and P01 DA035764. G.V. acknowledges TIPharma for financial supports. This work was also supported by COST Action CM1207 (GLISTEN). Kasper Harpsøe is acknowledged for discussions on structure superposition and residue numbering.

References

26 Wu, H. et al. (2014) Structure of a class B GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 344, 58–64
37 Malherbe, P. et al. (2006) Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlur5 receptor and identification of crucial residues involved in the inverse agonism of MPEP. J. Neurochem. 98, 601–615
64 Shimamura, T. et al. (2011) Structure of the human histamine H1 receptor complex with doxepin. *Nature* 475, 65–70
74 Vroling, B. et al. (2011) Integrating GPCR-specific information with full text articles. *BMC Bioinformatics* 12, 362